ELDN

Over the past six months, Eledon Pharmaceuticals experienced several stock-impacting events: Q1 2026 earnings were released on May 13, 2026. The Annual General Meeting on June 18, 2026, saw stockholders approve a share increase and board slate. In June 2026, long-term data from the Phase 2 BESTOW trial showed tegoprubart provided superior kidney function, fewer rejections, and a better safety profile compared to tacrolimus. Q2 2026 earnings on August 13, 2026, reported an EPS of -$0.27, missing analyst estimates and causing a 31.6% stock drop. An End-of-Phase 2 meeting with the FDA supported advancing tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026. In September 2026, tegoprubart received FDA Fast Track designation for kidney treatment, leading to a rise in shares. Updated long-term data from its Phase 2 BESTOW extension study was presented in September 2026. Cash, cash equivalents, and short-term investments decreased to $88.8 million by June 30, 2026, from $133.3 million at December 31, 2025, raising concerns about future funding and contributing to a 40% stock loss since June 30, 2026.